Activation of TREK-1 by morphine results in analgesia without adverse side effects. - Wikidata - wikimedia - TriplyDB

Activation of TREK-1 by morphine results in analgesia without adverse side effects.

Activation of TREK-1 by morphine results in analgesia without adverse side effects.

http://www.wikidata.org/entity/Q44003399

about

Feeling the hidden mechanical forces in lipid bilayer is an original sense Polyglycerol-opioid conjugate produces analgesia devoid of side effects Selective Small Molecule Activators of TREK-2 Channels Stimulate Dorsal Root Ganglion c-Fiber Nociceptor Two-Pore-Domain Potassium Channel Currents and Limit Calcium Influx.Prognostic significance of the TREK-1 K2P potassium channels in prostate cancer Mixing and matching TREK/TRAAK subunits generate heterodimeric K2P channels with unique properties.Aristolochic acid, a plant extract used in the treatment of pain and linked to Balkan endemic nephropathy, is a regulator of K2P channels.Enhanced Expression of TREK-1 Is Related with Chronic Constriction Injury of Neuropathic Pain Mouse Model in Dorsal Root Ganglion DAMGO modulates two-pore domain K(+) channels in the substantia gelatinosa neurons of rat spinal cord Two-pore domain potassium channels: potential therapeutic targets for the treatment of pain.K2P2.1 (TREK-1)-activator complexes reveal a cryptic selectivity filter binding site.Breaking barriers to novel analgesic drug development.Delta Opioid Receptor Expression and Function in Primary Afferent Somatosensory Neurons.GI-530159, a novel, selective, mechanosensitive two-pore-domain potassium (K2P ) channel opener, reduces rat dorsal root ganglion neuron excitability.

P2860

Q28658571-ED6AA1C7-F51F-4A64-9C35-3B742F531BC4 Q33870260-FF63BBFD-EC67-4108-8CA2-1FA50B0DD728 Q36180152-0C655926-68A1-4E68-9621-A35A2ECBAD91 Q36210906-C7DB8250-ECA0-4536-B073-1B1171DEDC2D Q36821471-81AE3627-9CDB-4A60-BC77-30FD3D1D0D3E Q36830145-BE3C0241-FD00-4980-BDF2-04F04FE20ADB Q36879174-87115E2A-152B-4AC6-B1AC-F29E4F331E00 Q37239786-BFC60E35-9FF1-4808-B0F0-A99EBA8E623A Q38270913-ACA5CA25-1853-4BB3-9729-8B6C59829A78 Q38686094-1855703A-7F88-435B-BFC9-B90F2068B4E8 Q39360773-56ACDE94-C7B6-4360-8851-57992E5FFDB2 Q43075846-47672CCB-C3C7-42F2-93BE-70B561D507DC Q48278693-AEA7B984-065E-4A58-BB2B-6F31FE22B840

P2860

Activation of TREK-1 by morphine results in analgesia without adverse side effects.

http://www.wikidata.org/entity/Q44003399

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Activation of TREK-1 by morphine results in analgesia without adverse side effects.

@en

Activation of TREK-1 by morphine results in analgesia without adverse side effects.

@nl

type

label

Activation of TREK-1 by morphine results in analgesia without adverse side effects.

@en

Activation of TREK-1 by morphine results in analgesia without adverse side effects.

@nl

prefLabel

Activation of TREK-1 by morphine results in analgesia without adverse side effects.

@en

Activation of TREK-1 by morphine results in analgesia without adverse side effects.

@nl

P1433

Q44003399-3EE553D9-4E44-40A1-B41C-9E39EC4AA25D

P1476

Q44003399-7E7ABF73-2DEE-410C-A09D-B23FA1C60CB7

P2093

Q44003399-1A2939E9-BFAF-4F82-83C5-D847D06B21C0

Q44003399-234C8FF8-71CB-4F55-92BB-79ACEDEDD978

Q44003399-29C85978-C557-4CDC-80BB-141EF0764203

Q44003399-2C6E8918-8968-4CAA-AEF9-85A4005D4CDC

Q44003399-3FCA096A-AE04-4D23-A2AF-8AF3F03DF3C4

Q44003399-44ABC6FA-1DDE-4F5F-B732-31D9E36E48F4

Q44003399-8263A074-7D63-4E08-985B-9614F310F25E

Q44003399-C7EF100F-6305-48AD-9B76-1E470DEF5697

Q44003399-D3E41DC8-B70E-4E2F-A570-1DE204E956A1

Q44003399-D4391C47-16ED-4D73-A110-756431ACE5F0

P2860

Q44003399-07785612-D11D-4654-9BFD-440CB12F5EFC

Q44003399-08C467DA-751D-433E-9923-C30D0B8D9776

Q44003399-0C842025-3762-4132-991A-4B6787E2B913

Q44003399-11F66878-0AEE-42D6-B08B-50B16D16D91F

Q44003399-1498ED73-CFFA-47AD-A321-F098FFDD55F0

Q44003399-17DED4C0-AF9D-40F8-B3F0-7AD3961FB454

Q44003399-30BE4D2B-91E6-4732-BD53-C71611372748

Q44003399-3963173E-33A0-40BB-87BB-582CECB946D6

Q44003399-3D0F981A-635B-4C48-A801-901EA2B025A4

Q44003399-3E6B28A6-951C-41E0-A423-E8287AF324AE

P2888

Q44003399-E4173526-16D2-4587-A006-D3B7B6E16356

P304

Q44003399-44D67A72-7C28-4A49-804E-A9C5A31433AA

P31

Q44003399-2DEB5C60-70C6-403B-B3E7-A5E3B41B3C50

P356

Q44003399-2359C5D1-038E-46E1-9643-24A5B54BCBCE

P407

Q44003399-618BB549-0129-4422-ABD9-D93E0DE29AAC

P478

Q44003399-E71F372A-841E-4626-BEB4-0F49795F957F

P577

Q44003399-1618F321-4451-4C3E-AEF1-4547FDFDF7D0

P5875

Q44003399-001EB68F-60C3-48BA-8263-983AFCC41E43

P6179

Q44003399-6529966D-3C6F-4BDE-ADD7-58AC6F365D05

P698

Q44003399-0628463F-87D7-489D-9416-BBE4B90371C7

P356

P1433

Nature Communications

P1476

Activation of TREK-1 by morphine results in analgesia without adverse side effects.

@en

P2093

Abdelkrim Alloui

http://www.w3.org/2001/XMLSchema#string

Alain Eschalier

http://www.w3.org/2001/XMLSchema#string

Bruno Mazet

http://www.w3.org/2001/XMLSchema#string

Emmanuel Deval

http://www.w3.org/2001/XMLSchema#string

Jacques Noel

http://www.w3.org/2001/XMLSchema#string

Jérôme Busserolles

http://www.w3.org/2001/XMLSchema#string

Marine Christin

http://www.w3.org/2001/XMLSchema#string

Maïly Devilliers

http://www.w3.org/2001/XMLSchema#string

Michel Lazdunski

http://www.w3.org/2001/XMLSchema#string

Patrick Delmas

http://www.w3.org/2001/XMLSchema#string

P2860

A mammalian two pore domain mechano-gated S-like K+ channel

Sequential phosphorylation mediates receptor- and kinase-induced inhibition of TREK-1 background potassium channels

The role of opioid receptor internalization and beta-arrestins in the development of opioid tolerance

Polyunsaturated fatty acids are potent neuroprotectors

Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence

The mechano-activated K+ channels TRAAK and TREK-1 control both warm and cold perception.

AKAP150, a switch to convert mechano-, pH- and arachidonic acid-sensitive TREK K(+) channels into open leak channels

Opioids in chronic non-cancer pain: systematic review of efficacy and safety.

Methylnaltrexone for opioid-induced constipation in advanced illness.

Opioids in pain management.

P2888

P304

2941

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCOMMS3941

http://www.w3.org/2001/XMLSchema#string

P407

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259352514

http://www.w3.org/2001/XMLSchema#string

P6179

1039011161

http://www.w3.org/2001/XMLSchema#string

P698

24346231

http://www.w3.org/2001/XMLSchema#string